BioLife Solutions (BLFS) AI Stock Analysis

• Market Cap: $991.62M
• Dividend Yield: N/A
• Average Volume (3M): 457.06K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.05
• Revenue Growth: -23.12%
• EPS Growth: 97.46%
• Country: US
• Employees: 159
• Sector: Healthcare
• Sector Strength: 37
• Industry: Medical - Instruments & Supplies
• EPS (TTM): -0.33
• Shares Outstanding: 47,835,213
• 10 Day Avg. Volume: 355,898
• 30 Day Avg. Volume: 457,061
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 1.02
• Enterprise Value/Revenue: 12.78
• Enterprise Value/Gross Profit: 16.70
• Enterprise Value/Ebitda: 299.30
• 1Y Price Target: $31.00
• Price Target Upside: 49.54% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 7

• Rating: 59 Neutral
• Price Target: $23.00 ▲(10.95% Upside)

BioLife Solutions' overall stock score reflects a blend of financial challenges and promising growth prospects. The strong earnings call and strategic acquisitions reinforce its positive trajectory, but financial struggles and technical weaknesses temper the outlook. Valuation concerns further impact the score negatively.

Positive Factors

Acquisition

The acquisition of PanTHERA CryoSolutions is expected to enhance BioLife's capabilities in cryopreservation solutions.

Analyst Confidence

Analyst reiterates a Buy rating and a $30 price target for BioLife Solutions, indicating confidence in the company's future performance.

Financial Performance

BioLife Solutions reported strong financial performance in 4Q24, with total revenue exceeding projections and a net loss lower than expected.

Negative Factors

Market Risks

Risks include lower-than-projected growth of products and services and potential fluctuation of sales in emerging markets.

Potential Dilution Risk

Risks include potential dilution risk that could affect shareholder value.

Revenue Decline

Total revenue was $23.9M, representing a 24.5% YoY decline and missing the projection of $26.0M.

BioLife Solutions Business Overview & Revenue Model

Company Description

BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage services. It markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was incorporated in 1987 and is headquartered in Bothell, Washington.

How the Company Makes Money

BioLife Solutions generates revenue primarily through the sale of its proprietary biopreservation media and automated thawing devices. The company's revenue streams include direct sales to biotechnology and pharmaceutical companies, as well as academic and government research institutions. Additionally, BioLife may engage in strategic partnerships and collaborations with other industry players to expand its market reach and enhance its product offerings. The company's earnings are significantly influenced by the growing demand for advanced cell therapies and regenerative medicine, as its products play a crucial role in maintaining cell integrity throughout the supply chain.

BioLife Solutions Financial Statement Overview

Summary

BioLife Solutions is facing declining revenues and persistent losses impacting profitability. While the gross profit margin remains strong and the balance sheet is stable with a high equity ratio, the negative revenue growth and profitability are concerning. However, improvements in cash flow management are notable.

Income Statement

BioLife Solutions has faced challenges in maintaining revenue growth, with a decline from $161.76M in 2022 to $79.42M in TTM (Trailing-Twelve-Months). The gross profit margin is strong at 76.5% in TTM, but the company is struggling with profitability as indicated by a negative net profit margin of -13.1% and negative EBIT and EBITDA margins. The revenue growth rate is negative, reflecting a downward trend in sales.

Balance Sheet

The company's balance sheet shows a solid equity base with a high equity ratio of 89.2% in TTM, indicating financial stability. However, the debt-to-equity ratio is low at 0.08, suggesting limited leverage. The return on equity is negative due to ongoing losses, which is a concern for investors.

Cash Flow

BioLife Solutions has improved its cash flow position, with a positive free cash flow of $11.29M in TTM, up from $5.20M in 2024. The operating cash flow to net income ratio is positive, indicating efficient cash generation relative to net income losses. The company has managed to grow its free cash flow significantly, which is a positive sign despite net losses.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	82.25M	143.27M	161.76M	119.16M	48.09M
Gross Profit	57.75M	46.75M	53.82M	37.75M	27.44M
EBITDA	1.53M	-45.24M	-23.19M	-17.78M	1.07M
Net Income	-20.18M	-66.43M	-139.81M	-8.38M	2.67M
Balance Sheet
Total Assets	399.49M	412.71M	450.23M	552.60M	234.83M
Cash, Cash Equivalents and Short-Term Investments	104.58M	51.70M	64.06M	69.87M	90.46M
Total Debt	30.17M	42.69M	43.71M	26.88M	11.15M
Total Liabilities	50.58M	75.05M	86.04M	71.85M	29.58M
Stockholders Equity	348.91M	337.66M	-246.91M	480.75M	205.25M
Cash Flow
Free Cash Flow	5.20M	-18.88M	-18.87M	-13.22M	1.88M
Operating Cash Flow	8.43M	-12.50M	-8.49M	-4.84M	6.51M
Investing Cash Flow	58.30M	17.84M	-58.12M	-12.64M	-23.73M
Financing Cash Flow	-6.78M	10.59M	16.32M	-2.78M	101.22M

BioLife Solutions Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 20.73
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BLFS, the sentiment is Negative. The current price of 20.73 is below the 20-day moving average (MA) of 21.62, below the 50-day MA of 21.93, and below the 200-day MA of 24.27, indicating a bearish trend. The MACD of -0.25 indicates Positive momentum. The RSI at 40.95 is Neutral, neither overbought nor oversold. The STOCH value of 23.47 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BLFS.

BioLife Solutions Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
STAA	63 Neutral	$1.34B	55.81	-25.55%	―	-14.44%	-557.38%
BLFS	59 Neutral	$991.62M	―	-3.29%	―	-23.12%	97.46%
Sector *	51 Neutral	$7.39B	0.40	-62.86%	2.37%	15.56%	-1.99%
AZTA	51 Neutral	$1.23B	―	-1.74%	―	-8.15%	13.50%
KMTS	45 Neutral	$814.39M	―	-130.38%	―	115.05%	-21.37%
PLSE	44 Neutral	$1.03B	―	-77.86%	―	―	-1.00%

BioLife Solutions Corporate Events

BioLife Solutions Strengthens Board with Tony J. Hunt Appointment

BioLife Solutions has appointed Tony J. Hunt, Executive Chairman of Repligen Corporation, to its board of directors effective January 2, 2025. Mr. Hunt, recognized for his leadership in bioprocessing innovation, is expected to enhance BioLife’s strategic focus on the CGT market with his extensive industry experience, contributing to the company’s growth and innovation efforts. This appointment reflects BioLife’s commitment to strengthening its position in the bioprocessing sector and supporting its mission of delivering top-tier bioproduction workflows.